RIDGEFIELD, Conn. and INDIANAPOLIS, March 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance ® (empagliflozin) ...

Jardiance and metformin help manage blood sugar levels in people with type 2 diabetes. Doctors commonly prescribe these medications together. Empagliflozin (the active ingredient in Jardiance) and ...

- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has ...

Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) Jardiance ® (empagliflozin) 10 mg tablets significantly reduced the risk ...

Jardiance (empagliflozin) is a prescription drug that’s used to manage blood sugar levels and lower certain risks. The drug comes as an oral tablet. It’s usually taken once per day. The active ...

- FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. with heart failure with preserved ejection fraction, which has been classified as "the single largest ...

Please provide your email address to receive an email when new articles are posted on . Jardiance had a 28% relative risk reduction for kidney disease progression vs. placebo. The drug also showed a ...

- Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. Jardiance is not ...